Skip to content

#心血管代谢

Today 0 items
Oct 14Wed
  1. biopharmadive.com56

    Another Paragon spinout goes public through reverse merger

    Alaunos Therapeutics acquired Velaris Therapeutics, Paragon Labs' ninth spinout, in a reverse merger that takes the cardiopulmonary disease drug developer public. Fairmount Funds, which founded Paragon in 2021, led a concurrent private placement of about $350 million, with investors including Venrock, Wellington Management and T. Rowe Price accounts, funding operations into 2029. Four of the combined company's five board directors will come from or be picked by Fairmount, and the business will advance Velaris' programs plus an obesity and metabolic disorder drug from Alaunos.

    Why it matters: Reverse mergers have surged to more than two dozen announced this year, matching IPO counts, and Velaris extends the Paragon-Fairmount model.

  2. biopharmadive.com64

    Roche extends China deal streak with $1B pact for RNAi obesity drug

    Roche licensed an experimental RNA interference obesity medicine targeting ALK7 from China-based Rona Therapeutics, paying $100 million upfront for full ownership and up to just over $1 billion in milestones plus royalties. The drug joins five other experimental obesity medicines in Roche's pipeline. It is Roche's fifth deal with a China-based drugmaker since the end of August and 10th since the beginning of 2025.

Oct 13Tue
  1. biospace.com65

    Roche expands obesity R&D footprint with Rona deal worth $1B+

    Roche has licensed an RNAi-based ALK7 obesity drug candidate from China's Rona Therapeutics, paying up to $100 million upfront and in near-term milestones plus as much as $1.06 billion in future milestones. ALK7 inhibition may reduce fat deposits while preserving muscle, an option GLP-1 drugs lack. The deal follows Roche returning its anti-myostatin therapy emugrobart to subsidiary Chugai after a mid-stage analysis found it unlikely to produce meaningful weight loss.

Oct 9Fri
  1. biospace.com54

    TRexBio, Retension raise $161.7M in IPOs; City, Iambic set proposed offering terms

    TRexBio raised $116.7 million in its Nasdaq IPO, selling 8.3 million shares at $14 to fund TRB-061, a fusion protein in early-stage development for atopic dermatitis with a Phase 1b topline readout expected mid-2027. Retension Pharmaceuticals raised $45 million at $12 per share to advance RTN-001, a PDE-5 blocker for hypertension, through Phase 2b and into Phase 3. City Therapeutics expects about $158.3 million and Iambic Therapeutics about $135 million from upcoming offerings.

    Why it matters: Four biotech IPOs in one week signal a reopening of the public markets for drug developers.

Oct 1Thu
  1. BioCentury66

    Novo gets shot at weekly obesity pill as Hengrui gets another MNC deal

    Novo Nordisk has in-licensed ex-China rights to a once-weekly oral dual agonist of GLP1R and GIPR from Jiangsu Hengrui Pharmaceuticals for $300 million up front, in one of the largest preclinical deals to date. The compound is intended for obesity, a core therapeutic area Novo Nordisk is building out through a series of deals this year. Hengrui continues its run of MNC partnerships.

    Why it matters: Large preclinical licensing deal with $300 million up front strengthens Novo Nordisk's obesity pipeline.

Sep 30Wed
  2. biopharmadive.com41

    Novo to pay Hengrui up to $2.6B for a once-weekly obesity pill

    Novo Nordisk is paying Hengrui Pharma $300 million up front and up to $2.6 billion in milestones for rights to HRS-1596, a once-weekly oral obesity drug that acts on GLP-1 and GIP. Novo gains rights outside China, Taiwan and nearby territories, aiming to challenge Eli Lilly's Zepbound. Described as Phase 1 ready, the drug has not been tested in humans and could be years from regulatory clearance.

Sep 29Tue
  1. statnews.com43

    STAT+: AstraZeneca invests $2 billion in Summit Therapeutics

    AstraZeneca has invested $2 billion in Summit Therapeutics, according to the headline of a STAT+ report. Separately, Novo Nordisk licensed a once-weekly oral GLP-1/GIP receptor agonist for obesity from Hengrui Pharma, paying $300 million upfront for global rights outside China, with total deal value of $2.6 billion if milestones are met; the drug is ready for Phase 1 development.

    Why it matters: AstraZeneca's $2 billion Summit stake and Novo's $2.6 billion obesity drug deal both move competitive pharma positioning.

  2. biospace.com45

    Novo adds long-term obesity differentiation in up to $2.6B Hengrui deal

    Novo Nordisk is licensing HRS-1596, Hengrui Pharma's once-weekly oral GLP-1R/GIPR dual agonist ready for Phase 1, paying $300 million upfront with the deal worth up to $2.6 billion in milestones plus royalties. The asset is intended for obesity, type 2 diabetes and other metabolic diseases, and China has already cleared it for a Phase 1 study in weight management and T2D. BMO Capital Markets says the deal is unlikely to change near-term competition but once-weekly oral dosing could offer longer-term differentiation.

  3. bsky.app42

    Signal or noise? > Novo agrees $2.6B deal for preclinical GLP-1/GIP drug from in-demand Hengrui >> Comment below! #strategy #competitiveintelligence #marketing #competitivemarketing #biotech #healthcare #pharma #pharmaceutical

    Novo has agreed a deal worth $2.6 billion with Hengrui for a preclinical GLP-1/GIP drug. Hengrui is described as an in-demand partner in the obesity and metabolic space. No further deal terms or timelines are given.

    Why it matters: Large licensing sum for a preclinical asset signals continued competition for GLP-1/GIP pipeline programs.

Sep 24Thu
  1. fiercebiotech.com42

    Roche pens backloaded $2B deal with Atavistik to discover allosteric CVRM drugs

    Roche has struck a licensing deal worth up to $2 billion with Atavistik Bio to discover allosteric small molecules for cardiovascular, renal and metabolic diseases. Roche pays $70 million up front, with up to $1.9 billion in milestones; the partners will use Atavistik's AMPS platform, with Atavistik handling discovery and Roche taking over preclinical work and beyond. The deal extends Roche's CVRM push, which includes the zilebesiran partnership with Alnylam, the $3.5 billion purchase of 89bio and the $2.7 billion Carmot takeover.

    Why it matters: Roche pays $70 million up front in a $2 billion deal to enter allosteric cardiometabolic drug discovery.

Sep 15Tue
  1. fiercebiotech.com52

    Novo walks away from $285M pact to develop monthly GLP-1 obesity drug with Ascendis

    Novo has walked away from a $285 million pact with Ascendis to develop a monthly GLP-1 obesity drug, ending the collaboration after less than two years. The deal had aimed to develop a longer-acting monthly weight loss treatment. The article gives no further details on what happens next.

    Why it matters: Novo terminated a $285 million GLP-1 obesity partnership with Ascendis, altering the competitive landscape for monthly weight loss drugs.

Sep 9Wed
  1. statnews.com47

    STAT+: Leukemia drug data suggested a different way to treat diabetes. A new biotech will test that idea

    Kura Oncology is spinning off its menin inhibitor programme into a new company, Caspian Therapeutics, which launches with $50 million in financing led by BVF Partners and joined by Eli Lilly. Animal studies of Kura's menin-targeting leukemia therapy showed the approach also helped control blood sugar, so Caspian will develop menin inhibitors for diabetes and other cardiometabolic diseases, taking its lead small molecule into an early-phase diabetes trial and backing a second candidate. Kura retains about 50% ownership, Kura CEO Troy Wilson becomes executive chair, and Robert Spencer was named to lead Caspian.

    Why it matters: A leukemia-derived menin inhibitor programme enters diabetes via a $50 million spinout with Eli Lilly involvement.

Sep 4Fri
  1. fiercebiotech.com52

    Menarini signs $771M deal to take Gan & Lee GLP-1 to European market

    Menarini Group will pay Gan & Lee Pharmaceuticals €62 million ($72 million) up front under a deal worth up to $771 million to register and commercialize Gan & Lee's GLP-1 bofanglutide in Europe. The Italian company takes the Chinese insulin maker's drug to the European market. Registration and commercialization work under the collaboration follows.

    Why it matters: Menarini pays Gan & Lee up to $771 million to bring its GLP-1 bofanglutide to Europe.

Aug 25Tue
  1. biocentury.com58

    Roche adds Hanmi’s obesity asset via licensing agreement: Deals Report

    Roche, through its Genentech unit, is paying Hanmi Pharmaceutical $190 million up front for rights to HM17321, a Ucn2 analog for obesity that has begun a Phase I trial in healthy volunteers and patients with obesity. Milestones could raise the deal's value to $2.3 billion, and Hanmi is eligible for royalties outside South Korea, where it retains the program's rights. The asset would complement at least four other clinical programs in Roche's obesity pipeline.

    Why it matters: A large pharma licensing a first-in-class obesity candidate with a $2.3 billion potential deal value.

Aug 22Sat
  1. biocentury.com49

    Buoyed by readout, Amylyx banks $500M ahead of submission: Finance Report

    Amylyx Pharmaceuticals (NASDAQ:AMLX) raised $500 million by selling 14.1 million shares at $35.50 in an upsized follow-on, having proposed $350 million. The raise follows Phase III data showing its GLP-1R antagonist avexitide met the primary endpoint in post-bariatric hypoglycemia, and funds are earmarked for an NDA submission planned this year and a subsequent launch.

CBACBA Frontier Insights (CFI)Chinese Biopharmaceutical Association (CBA)www.cba-usa.org